Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

14.50 +0.12 (+0.83%)
Streaming Delayed Price Updated: 12:00 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals
Via Benzinga
Expert Ratings For ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside. 
Via InvestorPlace
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Pharma Stocks to Sell in March Before They Crash & Burn
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions. 
Via InvestorPlace
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
From Acadia Pharmaceuticals Inc.
Via Business Wire
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Why Are Airline Stocks Down Today?
Airline stocks are down on Tuesday as investors deal with several bits of bad news for the industry on Tuesday! 
Via InvestorPlace
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin. 
Via InvestorPlace
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
The company says it doesn't plan to further develop Nuplazid in clinical testing. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fis 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday! 
Via InvestorPlace
Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details
Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations. 
Via Benzinga
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
From Acadia Pharmaceuticals Inc.
Via Business Wire
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch
CEO Steve Davis said there was a lot of pent-up demand when Daybue first launched last year. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.